560PImpact of Immune response-associated gene polymorphisms on tumor response in rectal cancer patients treated with capecitabine +/- oxaliplatine and radiation in the ACCORD-12/PRODIGE-2 phase III trial. (18th September 2017) - Valerie, B.; Mollevi, C.; Chaput, N.; Gourgou, S.; Azria, D.; Seitz, J.F.; Bigot, L.; Juzyna, B.; Miran, I.; Gérard, J-P.; Laurent-Puig, P.